Anna Molinder1,2, Doerthe Ziegelitz3, Stephan E Maier3,4, Carl Eckerström5,6. 1. Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. anna.molinder@vgregion.se. 2. Neuroradiology, Sahlgrenska sjukhuset, Blå stråket 5, Gothenburg, 413 46, Sweden. anna.molinder@vgregion.se. 3. Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 4. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 5. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 6. Department of Immunology and Transfusion Medicine, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
Abstract
BACKGROUND: Visual rating of medial temporal lobe atrophy (MTA) is often performed in conjunction with dementia workup. Most prior studies involved patients with known or probable Alzheimer's disease (AD). This study investigated the validity and reliability of MTA in a memory clinic population. METHODS: MTA was rated in 752 MRI examinations, of which 105 were performed in cognitively healthy participants (CH), 184 in participants with subjective cognitive impairment, 249 in subjects with mild cognitive impairment, and 214 in patients with dementia, including AD, subcortical vascular dementia and mixed dementia. Hippocampal volumes, measured manually or using FreeSurfer, were available in the majority of cases. Intra- and interrater reliability was tested using Cohen's weighted kappa. Correlation between MTA and quantitative hippocampal measurements was ascertained with Spearman's rank correlation coefficient. Moreover, diagnostic ability of MTA was assessed with receiver operating characteristic (ROC) analysis and suitable, age-dependent MTA thresholds were determined. RESULTS: Rater agreement was moderate to substantial. MTA correlation with quantitative volumetric methods ranged from -0.20 (p< 0.05) to -0.68 (p < 0.001) depending on the quantitative method used. Both MTA and FreeSurfer are able to distinguish dementia subgroups from CH. Suggested age-dependent MTA thresholds are 1 for the age group below 75 years and 1.5 for the age group 75 years and older. CONCLUSIONS: MTA can be considered a valid marker of medial temporal lobe atrophy and may thus be valuable in the assessment of patients with cognitive impairment, even in a heterogeneous patient population.
BACKGROUND: Visual rating of medial temporal lobe atrophy (MTA) is often performed in conjunction with dementia workup. Most prior studies involved patients with known or probable Alzheimer's disease (AD). This study investigated the validity and reliability of MTA in a memory clinic population. METHODS:MTA was rated in 752 MRI examinations, of which 105 were performed in cognitively healthy participants (CH), 184 in participants with subjective cognitive impairment, 249 in subjects with mild cognitive impairment, and 214 in patients with dementia, including AD, subcortical vascular dementia and mixed dementia. Hippocampal volumes, measured manually or using FreeSurfer, were available in the majority of cases. Intra- and interrater reliability was tested using Cohen's weighted kappa. Correlation between MTA and quantitative hippocampal measurements was ascertained with Spearman's rank correlation coefficient. Moreover, diagnostic ability of MTA was assessed with receiver operating characteristic (ROC) analysis and suitable, age-dependent MTA thresholds were determined. RESULTS: Rater agreement was moderate to substantial. MTA correlation with quantitative volumetric methods ranged from -0.20 (p< 0.05) to -0.68 (p < 0.001) depending on the quantitative method used. Both MTA and FreeSurfer are able to distinguish dementia subgroups from CH. Suggested age-dependent MTA thresholds are 1 for the age group below 75 years and 1.5 for the age group 75 years and older. CONCLUSIONS:MTA can be considered a valid marker of medial temporal lobe atrophy and may thus be valuable in the assessment of patients with cognitive impairment, even in a heterogeneous patient population.
Authors: Mark W Logue; Holly Posner; Richard C Green; Margaret Moline; L Adrienne Cupples; Katherine L Lunetta; Heng Zou; Stephen W Hurt; Lindsay A Farrer; Charles Decarli Journal: Alzheimers Dement Date: 2011-07-01 Impact factor: 21.566
Authors: C R Jack; R C Petersen; Y C Xu; S C Waring; P C O'Brien; E G Tangalos; G E Smith; R J Ivnik; E Kokmen Journal: Neurology Date: 1997-09 Impact factor: 9.910
Authors: M Bobinski; M J de Leon; J Wegiel; S Desanti; A Convit; L A Saint Louis; H Rusinek; H M Wisniewski Journal: Neuroscience Date: 2000 Impact factor: 3.590
Authors: C Eckerström; E Olsson; N Klasson; M Bjerke; M Göthlin; M Jonsson; S Rolstad; H Malmgren; A Wallin; A Edman Journal: Dement Geriatr Cogn Disord Date: 2011-02-03 Impact factor: 2.959
Authors: António J Bastos-Leite; Wiesje M van der Flier; Elisabeth C W van Straaten; Salka S Staekenborg; Philip Scheltens; Frederik Barkhof Journal: Stroke Date: 2007-10-25 Impact factor: 7.914
Authors: A T Du; N Schuff; M P Laakso; X P Zhu; W J Jagust; K Yaffe; J H Kramer; B L Miller; B R Reed; D Norman; H C Chui; M W Weiner Journal: Neurology Date: 2002-06-11 Impact factor: 9.910
Authors: M P Laakso; K Partanen; P Riekkinen; M Lehtovirta; E L Helkala; M Hallikainen; T Hanninen; P Vainio; H Soininen Journal: Neurology Date: 1996-03 Impact factor: 9.910
Authors: Nilton Custodio; Marco Malaga; Diego Chambergo-Michilot; Rosa Montesinos; Elizabeth Moron; Miguel A Vences; José Carlos Huilca; David Lira; Virgilio E Failoc-Rojas; Monica M Diaz Journal: Front Neurol Date: 2022-09-01 Impact factor: 4.086